Abstract:Key PointsThrough crosstalk with the intestinal microbiota, the innate immune system regulates intestinal homeostasis by conditioning the immune response both at mucosal sites and systemically, and by providing instructive signals that drive intestinal epithelial cell turnover and mucosal regeneration. The innate immune system is also a crucial modifier of bacterial handling through autophagy and a determinant of intestinal epithelial cell survival and apoptosis.Although excessive Toll-like receptor (TLR) activation in the gut is pathogenic, sensing of the commensal flora by these receptors, particularly TLR2 and TLR4, is required for intestinal homeostasis and control of tissue repair. In addition, apical TLR9 stimulation triggers mucosal tolerance through induction of type I interferons that have been proposed to protect from colonic inflammation.Nucleotide-binding oligomerization domain (NOD) receptors have a paramount role in intestinal homeostasis, and genetic mutations and single-nucleotide polymorphisms (SNPs) in their genes are associated with Crohn's disease. It is generally accepted that alterations in NOD2 function affect susceptibility to IBD because of the key role of this receptor in linking innate signals to the induction of adaptive immune tolerance to the intestinal microbiota. NOD2 modulates TLR signalling, regulates the production of defensins and IL-10, and polarizes the adaptive immune response towards a TH2-type response. More recently, NOD2 was shown to trigger autophagy in response to bacterial sensing through an interaction with the autophagy protein ATG16L1 (autophagy-related 16-like 1).Genetic studies of Crohn's disease, including genome-wide association studies, uncovered two autophagy loci — ATG16L1 and IRGM — that are linked to Crohn's disease susceptibility. Deficiency in ATG16L1 function not only affects the ability of NOD2 to trigger autophagy, but also affects Paneth cells and renders macrophages hyperresponsive to TLR agonists, which leads to excessive inflammasome activation. This suggests that aberrant bacterial handling could act as a trigger for inflammation in Crohn's disease.A SNP in the human NOD-, LRR- and pyrin domain-containing 3(NLRP3) region that downregulates NLRP3 expression is associated with Crohn's disease susceptibility. Consistently, the NLRP3 inflammasome–caspase 1–IL-18–IL-18R–MYD88 axis of inflammation is required for tissue repair following injury and is protective from colitis and colitis-associated colorectal cancer in mouse models.Negative regulators of innate immunity pathways, including SIGIRR (single immunoglobulin IL-1-related receptor), SOCS1 (suppressor of cytokine signalling 1) and caspase 12, are important effectors of intestinal immune tolerance. Deletion of their respective genes leads to amplification of the intestinal inflammatory response and promotion of colorectal cancer.

Non-coding RNAs as a Critical Player in the Regulation of Inflammasome in Inflammatory Bowel Diseases; Emphasize on lncRNAs

Role of long non-coding RNA in inflammatory bowel disease

Long non-coding RNAs as pathophysiological regulators, therapeutic targets and novel extracellular vesicle biomarkers for the diagnosis of inflammatory bowel disease

Systematic analysis and characterization of long non-coding RNA genes in inflammatory bowel disease

Biological functions of NLRP3 inflammasome: A therapeutic target in inflammatory bowel disease

Lnc-ing RNA to intestinal homeostasis and inflammation

Which long noncoding RNAs and circular RNAs contribute to inflammatory bowel disease?

NLRP3 inflammasome in colitis and colitis-associated colorectal cancer

NLRP3 Inflammasome and Inflammatory Bowel Disease

Medicinal Plants, Phytochemicals and Regulation of the NLRP3 Inflammasome in Inflammatory Bowel Diseases: A Comprehensive Review

Canonical and Non-Canonical Activation of NLRP3 Inflammasome at the Crossroad between Immune Tolerance and Intestinal Inflammation

Interplay between Cellular and Molecular Mechanisms Underlying Inflammatory Bowel Diseases Development-A Focus on Ulcerative Colitis

Targeting the NLRP3 inflammasome as new therapeutic avenue for inflammatory bowel disease

NLRP3: A Promising Therapeutic Target for Inflammatory Bowel Disease.

Transcriptomic landscape of lncRNAs in inflammatory bowel disease

NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis

Critical role for the NLRP3 inflammasome in colitis and colitis associated colorectal cancer (47.9)

Advances in Studies on NLRP3 Inflammasome in Inflammatory Bowel Disease

Innate immune mechanisms of colitis and colitis-associated colorectal cancer

NMI and IFP35 Are Key DAMP Molecules in Inflammatory Bowel Diseases

MicroRNA Post-transcriptional Regulation of the NLRP3 Inflammasome in Immunopathologies